Author(s): Priya Rastogi, MD1,2; Hanna Bandos, PhD3,4; Peter C. Lucas, MD, PhD1; Laura J. van ‘t Veer, PhD5; Jia-Perng J. Wei, MD, PhD5; Charles E. Geyer, Jr, MD1; Louis Fehrenbacher, MD6; Stephen K.L. Chia, MD7; Adam M. Brufsky, MD, PhD1,2; Janice M. Walshe, MD8; Gamini S. Soori, MD9; Shaker R. Dakhil, MD10; Soonmyung Paik, MD11,12; Sandra M. Swain, MD13; Andrea R. Menicucci, PhD5; M. William Audeh, MD5; Norman Wolmark, MD1; Eleftherios P. Mamounas, MD14
Author Affiliations
1UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA; 2Magee-Women’s Hospital, Pittsburgh, PA; 3NRG Oncology SDMC, Pittsburgh, PA; 4University of Pittsburgh, School of Public Health, Pittsburgh, PA; 5Agendia, Inc, Irvine, CA; 6Kaiser Permanente Oncology Clinical Trials Northern CA, Novato, CA; 7British Columbia Cancer Agency, Vancouver, BC, Canada; 8Cancer Trials Ireland, and St Vincent’s University Hospital, Dublin, Ireland; 9Florida Cancer Specialists, Fort Myers, FL; 10Wichita NCORP, Via Christi Regional Medical Center, and Cancer Center of Kansas, Wichita, KS; 11Theragenbio, Inc, Pankyo, Republic of Korea; 12Severance Biomedical Science Institute, Yonsei University College of Medicine, Seoul, Republic of Korea; 13Georgetown Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC; 14Advent Health Cancer Center, Orlando, FL